Presentations of pre|CISION® Platform Candidates

Summary by AI BETAClose X

Avacta Group PLC announced that it will present preclinical and translational data for its pre|CISION® platform candidates at the 2026 AACR Annual Meeting from April 17-22, 2026. Two presentations will detail AVA6103, a FAP-enabled peptide-drug conjugate delivering exatecan with sustained release and potent antitumor activity, and novel pre|CISION® compounds designed to deliver complementary dual payloads to the tumor microenvironment following FAP cleavage. These presentations highlight the company's progress in developing its tumor-activated oncology delivery platform.

Disclaimer*

UK 100

Latest directors dealings